8 unchanged sentences
However, the Company seeks fair compensation for Moderna’s use of its patented technology that was developed with great effort and at great expense, without which Moderna’s COVID-19 vaccine would not have been successful.
−Removed: Moderna has until May 6, 2022 to move, answer or otherwise respond to the complaint.
+Added: On May 6, 2022, Moderna filed a partial motion to dismiss the claims “relating to Moderna’s sale and provision of COVID-19 vaccine doses to the U.S.
+Added: Government.” The motion is now fully briefed.
+Added: No oral argument date has been set and no case schedule is yet in place.
Acuitas Declaratory Judgment Lawsuit
4 unchanged sentences
Acuitas also seeks a declaration that each of the listed patents is invalid.
−Removed: We have until June 24, 2022 to move, answer or otherwise respond to the complaint.
+Added: On June 24, 2022, Arbutus and Genevant sought a pre-motion conference concerning their anticipated motion to dismiss all of Acuitas’ claims due to lack of subject matter jurisdiction.
+Added: The request for a pre-motion conference was granted, but the case was subsequently re-assigned to a new judge who has not yet set a new pre-motion conference date.
+Added: No case schedule is yet in place.
+Added: University of British Columbia
+Added: Certain early work on lipid nanoparticle delivery systems and related inventions was undertaken at the University of British Columbia (“UBC”), as well as by us that was subsequently assigned to UBC.
+Added: These inventions are licensed to us by UBC under a license agreement, initially entered into in 1998 and as amended in 2001, 2006 and 2007.
+Added: We granted sublicenses under the UBC license to certain third parties, including Alnylam.
+Added: In November 2014, UBC filed a demand for arbitration against us which alleged entitlement to unpaid royalties.
+Added: In August 2019, the arbitrator issued his decision for the second phase of the arbitration, awarding UBC $5.9 million, which included interest of approximately $2.6 million.
+Added: We paid the $5.9 million award to UBC in September 2019 and paid an additional $0.2 million award for costs and attorneys’ fees in March 2021, and this matter is now fully resolved.
+Added: On December 18, 2020, UBC delivered to us a notice of arbitration alleging that under its cross license with us, it is due royalties of $2.0 million plus interest arising from our sale to OMERS of part of our royalty interest on future global net sales of ONPATTRO, currently being sold by Alnylam.
+Added: Oral hearings for this matter were held in April 2022 and, on July 11, 2022, the arbitrator issued his decision fully dismissing UBC’s claim for royalties.
+Added: As a result, no payments are owed to UBC and the Company intends to pursue an award for reimbursement of costs and attorneys’ fees.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.